ScandiDos AB (publ) (SDOS.ST)
SEK 1.64
(-1.2%)
SEK 1.64
(-1.2%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -13.35 Million SEK | -94.7% |
| 2022 | -8.26 Million SEK | -15.65% |
| 2021 | -7.1 Million SEK | -605.65% |
| 2020 | -1.57 Million SEK | 106.18% |
| 2019 | -12.72 Million SEK | 33.67% |
| 2018 | -16.93 Million SEK | -90.13% |
| 2017 | -6.57 Million SEK | 17.78% |
| 2016 | -7.99 Million SEK | 35.3% |
| 2015 | -12.36 Million SEK | 13.07% |
| 2014 | -14.22 Million SEK | -339.39% |
| 2013 | -3.39 Million SEK | -219.23% |
| 2012 | -1.01 Million SEK | -165.21% |
| 2011 | 1.55 Million SEK | -46.21% |
| 2010 | 2.89 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 188 Thousand SEK | 114.4% |
| 2023 Q1 | -4.81 Million SEK | -285.7% |
| 2023 FY | - SEK | -94.7% |
| 2023 Q4 | -1.95 Million SEK | -232.93% |
| 2023 Q3 | 1.47 Million SEK | 553.7% |
| 2023 Q2 | -324 Thousand SEK | 93.27% |
| 2022 Q4 | 2.59 Million SEK | 3605.41% |
| 2022 Q1 | -5.3 Million SEK | -761.36% |
| 2022 FY | - SEK | -15.65% |
| 2022 Q2 | -214 Thousand SEK | 95.97% |
| 2022 Q3 | -74 Thousand SEK | 65.42% |
| 2021 Q2 | -571 Thousand SEK | 71.56% |
| 2021 Q4 | -616 Thousand SEK | -202.16% |
| 2021 FY | - SEK | -605.65% |
| 2021 Q1 | -2 Million SEK | -108.52% |
| 2021 Q3 | 603 Thousand SEK | 205.6% |
| 2020 Q3 | 485 Thousand SEK | -81.03% |
| 2020 Q4 | -963 Thousand SEK | -298.56% |
| 2020 FY | - SEK | 106.18% |
| 2020 Q1 | 773 Thousand SEK | 128.77% |
| 2020 Q2 | 2.55 Million SEK | 230.79% |
| 2019 Q4 | -2.68 Million SEK | -674.35% |
| 2019 Q3 | -347 Thousand SEK | 87.76% |
| 2019 FY | - SEK | 33.67% |
| 2019 Q1 | -2.42 Million SEK | -327.79% |
| 2019 Q2 | -2.83 Million SEK | -16.86% |
| 2018 Q3 | -1.14 Million SEK | 77.27% |
| 2018 Q4 | 1.06 Million SEK | 193.01% |
| 2018 FY | - SEK | -90.13% |
| 2018 Q2 | -5.03 Million SEK | 31.8% |
| 2018 Q1 | -7.38 Million SEK | -824.93% |
| 2017 Q4 | 1.01 Million SEK | 154.93% |
| 2017 FY | - SEK | 17.78% |
| 2017 Q1 | -3.45 Million SEK | -120.19% |
| 2017 Q2 | -2.28 Million SEK | 33.93% |
| 2017 Q3 | -1.85 Million SEK | 18.78% |
| 2016 Q1 | -4.08 Million SEK | -21.02% |
| 2016 FY | - SEK | 35.3% |
| 2016 Q4 | -1.57 Million SEK | -56.22% |
| 2016 Q3 | -1 Million SEK | 25.11% |
| 2016 Q2 | -1.34 Million SEK | 67.12% |
| 2015 Q1 | -6.45 Million SEK | -53.09% |
| 2015 Q4 | -3.37 Million SEK | -128.83% |
| 2015 Q2 | -1.06 Million SEK | 83.57% |
| 2015 Q3 | -1.47 Million SEK | -38.93% |
| 2015 FY | - SEK | 13.07% |
| 2014 FY | - SEK | -339.39% |
| 2014 Q4 | -4.21 Million SEK | -206.91% |
| 2014 Q2 | -3.42 Million SEK | 34.35% |
| 2014 Q1 | -5.21 Million SEK | -86.31% |
| 2014 Q3 | -1.37 Million SEK | 59.84% |
| 2013 Q4 | -2.79 Million SEK | -344.92% |
| 2013 FY | - SEK | -219.23% |
| 2013 Q1 | -921 Thousand SEK | -262.72% |
| 2013 Q2 | -661 Thousand SEK | 28.23% |
| 2013 Q3 | 1.14 Million SEK | 272.77% |
| 2012 Q4 | 566 Thousand SEK | 138.24% |
| 2012 Q3 | -1.48 Million SEK | 0.0% |
| 2012 FY | - SEK | -165.21% |
| 2011 FY | - SEK | -46.21% |
| 2010 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | 82.682% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 103.243% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 103.243% |
| Arcoma AB | 6.24 Million SEK | 313.764% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | 85.157% |
| BICO Group AB (publ) | 322.3 Million SEK | 104.144% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 120.243% |
| CellaVision AB (publ) | 207.24 Million SEK | 106.445% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | 80.475% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | 52.203% |
| C-Rad AB (publ) | 48.9 Million SEK | 127.311% |
| Duearity AB (publ) | -24.77 Million SEK | 46.1% |
| Dignitana AB (publ) | -264 Thousand SEK | -4959.091% |
| Episurf Medical AB (publ) | -87.7 Million SEK | 84.771% |
| Getinge AB (publ) | 5.92 Billion SEK | 100.225% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | 80.14% |
| Iconovo AB (publ) | -35.33 Million SEK | 62.202% |
| Integrum AB (publ) | 8.76 Million SEK | 252.439% |
| Luxbright AB (publ) | -23.86 Million SEK | 44.039% |
| Mentice AB (publ) | 28.87 Million SEK | 146.258% |
| OssDsign AB (publ) | -122.02 Million SEK | 89.054% |
| Paxman AB (publ) | 31.22 Million SEK | 142.768% |
| Promimic AB (publ) | -3.68 Million SEK | -262.541% |
| Qlife Holding AB (publ) | -150.5 Million SEK | 91.126% |
| SciBase Holding AB (publ) | -51.82 Million SEK | 74.231% |
| Sectra AB (publ) | 615.06 Million SEK | 102.171% |
| Sedana Medical AB (publ) | -51.67 Million SEK | 74.153% |
| Senzime AB (publ) | -118.82 Million SEK | 88.76% |
| SpectraCure AB (publ) | -20.96 Million SEK | 36.306% |
| Stille AB | 56.04 Million SEK | 123.833% |
| Vitrolife AB (publ) | -3.18 Billion SEK | 99.581% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 110.552% |